A Phase 2, open-label, multicenter, randomized study to evaluate lenacapavir, a medication given as twice-yearly long-acting shots versus the standard oral medication (tenofovir/emtricitabine) used for prevention of HIV in cisgender women in the United States. The study is fully enrolled and nearing the end of the randomized phase. During this study, lenacapavir received FDA approval as PrEP (pre-exposure prevention) for women and men at risk of acquiring HIV through sex. It is now increasingly available in the community.
